Long-acting injectable antipsychotics: more effective than oral medications at preventing hospitalisation and relapse in schizophrenia according to new review

firemonkey · July 19, 2021, 2:21pm

everhopeful · July 19, 2021, 2:25pm

Thought the last paragraph was interesting.

It is possible that LAIs administered once or twice a month might offer an advantage due to more frequent contact and monitoring by clinicians compared to OAM. While outpatient visit frequency is likely to be standardised in an RCT, there may be substantial disparity in visit frequency when using LAI vs. OAM in real-world settings and non-RCT clinical trial designs. Accordingly, it will be important to determine if LAIs that are now available to be given every 3-months, can sustain the benefit of LAIs compared to OAM (or more frequently dosed LAIs), either in future clinical research or “real-world” practice.